Dr. Amir Fathi is Director of the Leukemia Program at Massachusetts General Hospital and an Associate Professor of Medicine at Harvard Medical School in Boston, Massachusetts. He earned his medical degree from the Yale University School of Medicine in New Haven, Connecticut, residency training at Massachusetts General Hospital in Boston, and a fellowship in hematology/oncology from Johns Hopkins Hospital in Baltimore, Maryland, and a Master of Science degree in Epidemiology from the Harvard T. H. Chan School of Public Health in Boston.

Dr. Fathi’s research includes conducting clinical trials of novel therapies and engaging in translational research in the fields of leukemia and bone marrow diseases. He leads multiple clinical trials for such patients at the Dana Farber Harvard Cancer Center, with specific interest in aurora kinase inhibition, FLT3 inhibition, IDH-inhibition, and antibody-drug conjugates as novel therapeutic approaches for patients with acute leukemias. He has authored/coauthored more than 125 peer-review articles on acute myeloid leukemia and other leukemias and bone marrow diseases.

Dr. Naval Daver is an Associate Professor in the Department of Leukemia at MD Anderson Cancer Center. He completed his medical school from Grant Medical College and Sir J group of Hospitals Mumbai, followed by a residency and fellowship in hematology-oncology from Baylor College of Medicine. He is a clinical investigator with a focus on molecular and immune therapies in AML and Myelofibrosis and is principal investigator on >25 ongoing institutional, national and international clinical trials in these diseases. These trials focus on developing a personalized therapy approach by targeting specific mutations or immune pathways expressed by patients with AML, evaluating novel combinations of targeted, immune and cytotoxic agents, and identifying and overcoming mechanism of resistance. He is especially interested in developing monoclonal and bispecific antibodies, immune checkpoint and vaccine based approaches in AML, MDS, and myelofibrosis and is leading a number of these trials at MDACC. Dr. Daver has published >150 peer-reviewed manuscripts and is on the editorial board of numerous hematology specific journals. He has also authored numerous abstracts at national and international conferences.